MedTrace Logo

Phase III Clinical Study of Domestic Recombinant Human Follitropin for Injection to Treat WHO Class II Anovulation

NCT02335879 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 534

Last updated 2015-01-12

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of Domestic Recombinant Human Follitropin (Gonal-F) for Injection for treatment of WHO Ⅱ anovulation (including polycystic ovarian syndrome \[PCOS\] subjects).

Conditions

  • Anovulation

Interventions

BIOLOGICAL

Gonal-F

Sponsors & Collaborators

  • Peking University People's Hospital

    collaborator OTHER

  • Peking University First Hospital

    collaborator OTHER

  • Reproductive & Genetic Hospital of CITIC-Xiangya

    collaborator OTHER

  • Qilu Hospital of Shandong University

    collaborator OTHER

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    collaborator OTHER

  • Second Hospital of Jilin University

    collaborator OTHER

  • Shengjing Hospital

    collaborator OTHER

  • The First Affiliated Hospital of Dalian Medical University

    collaborator OTHER

  • Second Affiliated Hospital of Wenzhou Medical University

    collaborator OTHER

  • Changchun GeneScience Pharmaceutical Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Max Age
38 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-05-31
Primary Completion
2009-08-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02335879 on ClinicalTrials.gov